Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
Tianyao Lei,
Tianwei Xu,
Niu Zhang,
Xiaoteng Zou,
Ziyue Kong,
Chenchen Wei,
Zhaoxia Wang
Affiliations
Tianyao Lei
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Tianwei Xu
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Niu Zhang
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Xiaoteng Zou
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Ziyue Kong
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Chenchen Wei
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
Zhaoxia Wang
Correspondence to: Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, PR China.; Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China
